Opioid antagonist

Results: 102



#Item
81

PDF Document

Add to Reading List

Source URL: www.dhhs.nh.gov

Language: English - Date: 2014-02-25 14:37:29
82HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EVZIO safely and effectively. See full prescribing information for EVZIO. EVZIO (naloxone hydrochloride injection) A

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EVZIO safely and effectively. See full prescribing information for EVZIO. EVZIO (naloxone hydrochloride injection) A

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-04-03 11:33:57
83Statewide Opioid Antagonist Community Access Program Intranasal Naloxone Administration Training Module

Statewide Opioid Antagonist Community Access Program Intranasal Naloxone Administration Training Module

Add to Reading List

Source URL: www.healthvermont.gov

Language: English - Date: 2014-04-04 09:08:12
84Education and Training Module for Ohio EMS  Developed in the 1960s  Opioid antagonist  Emergent overdose treatment in the

Education and Training Module for Ohio EMS  Developed in the 1960s  Opioid antagonist  Emergent overdose treatment in the

Add to Reading List

Source URL: www.publicsafety.ohio.gov

Language: English - Date: 2014-06-18 15:48:53
85Statewide Opioid Antagonist Community Access Program Intranasal Administration Training Module

Statewide Opioid Antagonist Community Access Program Intranasal Administration Training Module

Add to Reading List

Source URL: healthvermont.gov

Language: English - Date: 2014-04-07 13:30:35
86Initial REMS Approval: December[removed]NDA[removed]SUBUTEX® (buprenorphine) sublingual tablet CIII Buprenorphine (opioid partial agonist-antagonist)

Initial REMS Approval: December[removed]NDA[removed]SUBUTEX® (buprenorphine) sublingual tablet CIII Buprenorphine (opioid partial agonist-antagonist)

Add to Reading List

Source URL: www.fda.gov

Language: English
87Initial REMS Approved: March[removed]Most Recent Modification: July 2013 NDA[removed]VIVITROL® (naltrexone for extended-release injectable suspension) Opioid Antagonist

Initial REMS Approved: March[removed]Most Recent Modification: July 2013 NDA[removed]VIVITROL® (naltrexone for extended-release injectable suspension) Opioid Antagonist

Add to Reading List

Source URL: www.fda.gov

Language: English
88SUBOXONE® (buprenorphine and naloxone) sublingual film CIII Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioid antagonist)

SUBOXONE® (buprenorphine and naloxone) sublingual film CIII Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioid antagonist)

Add to Reading List

Source URL: www.fda.gov

Language: English
89Development of fluorophoric and bivalent ligands at OP receptors: mobility and dynamics studies Primary Supervision: Michael Decker Secondary Supervisor: Davide Calebiro Lab webpage: http://www.pharmazie.uni-wuerzburg.de

Development of fluorophoric and bivalent ligands at OP receptors: mobility and dynamics studies Primary Supervision: Michael Decker Secondary Supervisor: Davide Calebiro Lab webpage: http://www.pharmazie.uni-wuerzburg.de

Add to Reading List

Source URL: www.graduateschools.uni-wuerzburg.de

Language: English - Date: 2014-05-13 11:14:11
90NCI Conference: Low Dose Opioid Blockers, Endorphins and Metenkephalins “Promising Compounds for Unmet Medical Needs” Executive Plaza North Bethesda, MD[removed]Attendees

NCI Conference: Low Dose Opioid Blockers, Endorphins and Metenkephalins “Promising Compounds for Unmet Medical Needs” Executive Plaza North Bethesda, MD[removed]Attendees

Add to Reading List

Source URL: lowdosenaltrexone.org

Language: English - Date: 2007-07-07 12:12:57